GlobalResearch and clinical trials
Gene therapy in choroideremia: a pooled analysis of 11 studies shows a small gain in vision
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
A total of 11 studies examining gene therapy given into the eye in choroideremia were evaluated together. There were data on 308 people in total. Visual acuity improved by about three letters on average. Progression of damage in the retina slowed. Side effects occurred in about one in three people, and most were mild.
What does it mean for patients and families?
Gene therapy appears to slow loss rather than restore it. This treatment is not yet approved, and studies are ongoing. You can ask your eye doctor about clinical trials.
Source
Scientific paper: Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis. EClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103923 · PubMed 42180403
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Choroideremia
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.